Maternal Respiratory Syncytial Virus (RSV) Vaccination: Current Status and Comparison to Monoclonal Antibodies (mAbs) for RSV Prevention in Infants and Children

1. Aliprantis AO, Shaw CA, Griffin P, Farinola N, Railkar RA, Cao X, et al. A phase 1, randomized, placebo-controlled study to evaluate the safety and immunogenicity of an mRNA-based RSV prefusion F protein vaccine in healthy younger and older adults. Hum. Vaccines Immunother. 2021;17(5):1248–1261. AliprantisAO ShawCA GriffinP FarinolaN RailkarRA CaoX A phase 1, randomized, placebo-controlled study to evaluate the safety and immunogenicity of an mRNA-based RSV prefusion F protein vaccine in healthy younger and older adults Hum. Vaccines Immunother 2021 17 5 1248 1261 Search in Google Scholar

2. Shaw CA, Ciarlet M, Cooper BW, Dionigi L, Keith P, O'Brien KB, et al. The path to an RSV vaccine. Curr. Opin. Virol. 2013;3(3):332–342. ShawCA CiarletM CooperBW DionigiL KeithP O'BrienKB The path to an RSV vaccine Curr. Opin. Virol 2013 3 3 332 342 Search in Google Scholar

3. Carroll KN, Wu P, Gebretsadik T, Griffin MRF, Dupont Wd, Mitchel EF, et al. The severity-dependent relationship of infant bronchiolitis on the risk and morbidity of early childhood asthma. J. Allergy Clin. Immunol. 2009;123(5):1055–1061, 1061.e1. CarrollKN WuP GebretsadikT GriffinMRF DupontWd MitchelEF The severity-dependent relationship of infant bronchiolitis on the risk and morbidity of early childhood asthma J. Allergy Clin. Immunol 2009 123 5 1055 1061 1061.e1 Search in Google Scholar

4. Lozano, R. Naghavi M, Foreman K, Lim S, Shibuya K, Aboyans V, et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: A systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012;380(9859):2095–2128. LozanoR NaghaviM ForemanK LimS ShibuyaK AboyansV Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: A systematic analysis for the Global Burden of Disease Study 2010 Lancet 2012 380 9859 2095 2128 Search in Google Scholar

5. Shi, T, McAllister DA, O'Brien KL, Simoes EA, Madhi SA, Gessner BD, et al. Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in young children in 2015: a systematic review and modelling study. Lancet Lond. Engl. 2017;390(10098):946–958. ShiT McAllisterDA O'BrienKL SimoesEA MadhiSA GessnerBD Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in young children in 2015: a systematic review and modelling study Lancet Lond. Engl 2017 390 10098 946 958 Search in Google Scholar

6. NIAID: National Institute of Allergy and Infectious Disease. Respiratory Syncytial Virus (RSV): https://www.niaid.nih.gov/diseases-conditions/respiratory-syncytial-virus-rsv. NIAID: National Institute of Allergy and Infectious Disease Respiratory Syncytial Virus (RSV): https://www.niaid.nih.gov/diseases-conditions/respiratory-syncytial-virus-rsv. Search in Google Scholar

7. Falsey AR, Walsh EE. Respiratory syncytial virus infection in adults. 2000; Clin. Microbiol. Rev. 13(3):371–384. FalseyAR WalshEE Respiratory syncytial virus infection in adults 2000 Clin. Microbiol. Rev. 13 3 371 384 Search in Google Scholar

8. Battles, MB, McLellan, JS. Respiratory syncytial virus entry and how to block it. Nat. Rev. Microbiol. 2019; 17(4):233–245. BattlesMB McLellanJS Respiratory syncytial virus entry and how to block it Nat. Rev. Microbiol 2019 17 4 233 245 Search in Google Scholar

9. Levine S, Klaiber-Franco R, Paradiso PR. Demonstration that glycoprotein G is the attachment protein of respiratory syncytial virus. J. Gen. Virol. 1987;68 (Pt 9):2521–2524. LevineS Klaiber-FrancoR ParadisoPR Demonstration that glycoprotein G is the attachment protein of respiratory syncytial virus J. Gen. Virol 1987 68 Pt 9 2521 2524 Search in Google Scholar

10. Efstathiou C, Abidi SH, Harker J, Stevenson NJ. Revisiting respiratory syncytial virus's interaction with host immunity, towards novel therapeutics. Cell. Mol. Life Sci. 2020;CMLS 77(24):5045–5058. EfstathiouC AbidiSH HarkerJ StevensonNJ Revisiting respiratory syncytial virus's interaction with host immunity, towards novel therapeutics Cell. Mol. Life Sci 2020 CMLS 77 24 5045 5058 Search in Google Scholar

11. Ouyang Y, Liao H, Hu Y, Luo K, Hu S, Zhu H. Innate Immune Evasion by Human Respiratory Syncytial Virus. Front. Microbiol. 2022;13:865592. OuyangY LiaoH HuY LuoK HuS ZhuH Innate Immune Evasion by Human Respiratory Syncytial Virus Front. Microbiol 2022 13 865592 Search in Google Scholar

12. Killikelly A, Tunis M, House A, Quach C, Vaudy W, Moore D. Overview of the respiratory syncytial virus vaccine candidate pipeline in Canada. Can. Commun. Dis. Rep. Releve Mal. Transm. Au Can. 2020;46(4):56–61. KillikellyA TunisM HouseA QuachC VaudyW MooreD Overview of the respiratory syncytial virus vaccine candidate pipeline in Canada Can. Commun. Dis. Rep. Releve Mal. Transm. Au Can 2020 46 4 56 61 Search in Google Scholar

13. Díez-Domingo J, Sáez-Llorens X, Rodriguez-Weber MA, Epalza C, Chatterjee A, Chiu CH, et al. Safety and immunogenicity of a ChAd155-vectored respiratory syncytial virus (RSV) vaccine in healthy RSV-seropositive children 12–23 months of age. J. Infect. Dis. 2023;227(11):1293–1302. Díez-DomingoJ Sáez-LlorensX Rodriguez-WeberMA EpalzaC ChatterjeeA ChiuCH Safety and immunogenicity of a ChAd155-vectored respiratory syncytial virus (RSV) vaccine in healthy RSV-seropositive children 12–23 months of age J. Infect. Dis 2023 227 11 1293 1302 Search in Google Scholar

14. Cunningham CK, Karron R, Muresan P, McFarland EJ, Perlowski C, Libous J, et al. Live-attenuated respiratory syncytial virus vaccine with deletion of RNA synthesis regulatory protein M2-2 and cold passage mutations is overattenuated. Open Forum Infect. Dis. 2019;6(6)A:ofz212. CunninghamCK KarronR MuresanP McFarlandEJ PerlowskiC LibousJ Live-attenuated respiratory syncytial virus vaccine with deletion of RNA synthesis regulatory protein M2-2 and cold passage mutations is overattenuated Open Forum Infect. Dis 2019 6 6 A:ofz212. Search in Google Scholar

15. Belshe RB, Van Voris, LP, Mufson MA. Parenteral administration of live respiratory syncytial virus vaccine: results of a field trial. J. Infect. Dis. 1982;145(3):311–319. BelsheRB Van VorisLP MufsonMA Parenteral administration of live respiratory syncytial virus vaccine: results of a field trial J. Infect. Dis 1982 145 3 311 319 Search in Google Scholar

16. Groothuis JR, King SJ, Hogerman DA, Paradiso PR, Simoes EA. Safety and immunogenicity of a purified F protein respiratory syncytial virus (PFP-2) vaccine in seropositive children with bronchopulmonary dysplasia. J. Infect. Dis. 19998;177(2): 467–469. GroothuisJR KingSJ HogermanDA ParadisoPR SimoesEA Safety and immunogenicity of a purified F protein respiratory syncytial virus (PFP-2) vaccine in seropositive children with bronchopulmonary dysplasia J. Infect. Dis 19998 177 2 467 469 Search in Google Scholar

17. Tristram DA, Welliver RC, Mohar CK, Hogerman DA, Hildreth SW, Paradiso P. Immunogenicity and safety of respiratory syncytial virus subunit vaccine in seropositive children 18–36 months old. J. Infect. Dis. 1993;167(1):191–195. TristramDA WelliverRC MoharCK HogermanDA HildrethSW ParadisoP Immunogenicity and safety of respiratory syncytial virus subunit vaccine in seropositive children 18–36 months old J. Infect. Dis 1993 167 1 191 195 Search in Google Scholar

18. Kim HW, Canchola JG, Brandt CD, Pyles G, Chanock RM, K Jensen, et al. Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine. Am. J. Epidemiol. 1969;89(4):422–434. KimHW CancholaJG BrandtCD PylesG ChanockRM JensenK Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine Am. J. Epidemiol 1969 89 4 422 434 Search in Google Scholar

19. Graham BS. Vaccine development for respiratory syncytial virus. Curr. Opin. Virol. 2017;23:107–112. GrahamBS Vaccine development for respiratory syncytial virus Curr. Opin. Virol 2017 23 107 112 Search in Google Scholar

20. Tang RS, Spaete RR, Thompson MW, MacPhail M, Guzzetta JM, Ryan PC, et al. Development of a PIV-vectored RSV vaccine: preclinical evaluation of safety, toxicity, and enhanced disease and initial clinical testing in healthy adults. Vaccine. 2008;26(50):6373–6382. TangRS SpaeteRR ThompsonMW MacPhailM GuzzettaJM RyanPC Development of a PIV-vectored RSV vaccine: preclinical evaluation of safety, toxicity, and enhanced disease and initial clinical testing in healthy adults Vaccine 2008 26 50 6373 6382 Search in Google Scholar

21. Wright PF, Karron RA, Belshe RB, Shi JR, Randolph VB, Collins PL, et al. The absence of enhanced disease with wild type respiratory syncytial virus infection occurring after receipt of live, attenuated, respiratory syncytial virus vaccines. Vaccine. 2007; 25(42):7372–7378. WrightPF KarronRA BelsheRB ShiJR RandolphVB CollinsPL The absence of enhanced disease with wild type respiratory syncytial virus infection occurring after receipt of live, attenuated, respiratory syncytial virus vaccines Vaccine 2007 25 42 7372 7378 Search in Google Scholar

22. Cunningham CK, Karron RA, Muresan P, Kelly MS, McFarland EJ, Perlowski C. Evaluation of recombinant live-attenuated respiratory syncytial virus (RSV) vaccines RSV/ΔNS2/Δ1313/I1314L and RSV/276 in RSV-seronegative children. J. Infect. Dis. 2022;226(12):2069–2078. CunninghamCK KarronRA MuresanP KellyMS McFarlandEJ PerlowskiC Evaluation of recombinant live-attenuated respiratory syncytial virus (RSV) vaccines RSV/ΔNS2/Δ1313/I1314L and RSV/276 in RSV-seronegative children J. Infect. Dis 2022 226 12 2069 2078 Search in Google Scholar

23. McFarland EJ, Karron RA, Muresan P, Cunningham CK, Valentgine ME, Perlowski C, et al. Live-attenuated respiratory syncytial virus vaccine candidate with deletion of RNA synthesis regulatory protein M2-2 is highly immunogenic in children. J. Infect. Dis. 2018;217(9):13470–1355. McFarlandEJ KarronRA MuresanP CunninghamCK ValentgineME PerlowskiC Live-attenuated respiratory syncytial virus vaccine candidate with deletion of RNA synthesis regulatory protein M2-2 is highly immunogenic in children J. Infect. Dis 2018 217 9 13470 1355 Search in Google Scholar

24. McFarland, EJ, Karron RA, Muresan P, Cunningham CK, Perlowski C, Libous J, et al. Live-Attenuated respiratory syncytial virus vaccine with M2-2 deletion and with small hydrophobic noncoding region is highly immunogenic in children. J. Infect. Dis. 2020;221(12):2050–2059. McFarlandEJ KarronRA MuresanP CunninghamCK PerlowskiC LibousJ Live-Attenuated respiratory syncytial virus vaccine with M2-2 deletion and with small hydrophobic noncoding region is highly immunogenic in children J. Infect. Dis 2020 221 12 2050 2059 Search in Google Scholar

25. Malkin E, Yogev R, Abughali N, Sliman J, Wang CK, Zuo F, et al. Safety and immunogenicity of a live attenuated RSV vaccine in healthy RSV-seronegative children 5 to 24 months of age. PloS One. 2013; 8(10):e77104. MalkinE YogevR AbughaliN SlimanJ WangCK ZuoF Safety and immunogenicity of a live attenuated RSV vaccine in healthy RSV-seronegative children 5 to 24 months of age PloS One 2013 8 10 e77104 Search in Google Scholar

26. American Academy of Pediatrics Committee on Infectious Diseases & American Academy of Pediatrics Bronchiolitis Guidelines Committee. Updated guidance for palivizumab prophylaxis among infants and young children at increased risk of hospitalization for respiratory syncytial virus infection. Pediatrics. 2014;134:e620–638. American Academy of Pediatrics Committee on Infectious Diseases & American Academy of Pediatrics Bronchiolitis Guidelines Committee Updated guidance for palivizumab prophylaxis among infants and young children at increased risk of hospitalization for respiratory syncytial virus infection Pediatrics 2014 134 e620 638 Search in Google Scholar

27. CDC Health Alert Network (HAN). Limited Availability of Nirsevimab in the United States—Interim CDC Recommendations to Protect Infants from Respiratory Syncytial Virus (RSV) during the 2023–2024 Respiratory Virus Season: https://www.cdc.gov/han/2023/han00499.html (2024). CDC Health Alert Network (HAN) Limited Availability of Nirsevimab in the United States—Interim CDC Recommendations to Protect Infants from Respiratory Syncytial Virus (RSV) during the 2023–2024 Respiratory Virus Season https://www.cdc.gov/han/2023/han00499.html 2024 Search in Google Scholar

28. Sun, M, Lai H, Na F, Li S, Qiu X, Tian J, et al. Monoclonal antibody for the prevention of respiratory syncytial virus in infants and children: A systematic review and network meta-analysis. JAMA Netw. Open. 2023;6(2):e230023. SunM LaiH NaF LiS QiuX TianJ Monoclonal antibody for the prevention of respiratory syncytial virus in infants and children: A systematic review and network meta-analysis JAMA Netw. Open 2023 6 2 e230023 Search in Google Scholar

29. Fernández P, Trenholme A, Abarca K, Griffin MP, Hultquist M, Harris B, et al. A phase 2, randomized, double-blind safety and pharmacokinetic assessment of respiratory syncytial virus (RSV) prophylaxis with motavizumab and palivizumab administered in the same season. BMC Pediatr. 2010;10:38. FernándezP TrenholmeA AbarcaK GriffinMP HultquistM HarrisB A phase 2, randomized, double-blind safety and pharmacokinetic assessment of respiratory syncytial virus (RSV) prophylaxis with motavizumab and palivizumab administered in the same season BMC Pediatr 2010 10 38 Search in Google Scholar

30. Munoz FM, Englund JA. Respiratory syncytial virus. Matern. Immun. 2019;213–234. doi: 10.1016/B978-0-12-814582-1.00011-5. MunozFM EnglundJA Respiratory syncytial virus Matern. Immun 2019 213 234 10.1016/B978-0-12-814582-1.00011-5 Open DOISearch in Google Scholar

31. Chu HY, Tielsch J, Katz J, Margaret AS, Khatry S, LeClerq SC, et al. Transplacental transfer of maternal respiratory syncytial virus (RSV) antibody and protection against RSV disease in infants in rural Nepal. J. Clin. Virol. Off. Publ. Pan Am. Soc. Clin. Virol. 2017;95:90–95. ChuHY TielschJ KatzJ MargaretAS KhatryS LeClerqSC Transplacental transfer of maternal respiratory syncytial virus (RSV) antibody and protection against RSV disease in infants in rural Nepal J. Clin. Virol. Off. Publ. Pan Am. Soc. Clin. Virol 2017 95 90 95 Search in Google Scholar

32. Glezen WP, Paredes A, Allison, JE, Taber LH, Frank AL. Risk of respiratory syncytial virus infection for infants from low-income families in relationship to age, sex, ethnic group, and maternal antibody level. J. Pediatr. 1981;98(5):708–715. GlezenWP ParedesA AllisonJE TaberLH FrankAL Risk of respiratory syncytial virus infection for infants from low-income families in relationship to age, sex, ethnic group, and maternal antibody level J. Pediatr 1981 98 5 708 715 Search in Google Scholar

33. Aranda SS, Polack FP. Prevention of pediatric respiratory syncytial virus lower respiratory tract illness: Perspectives for the next decade. Front. Immunol. 2019;10:1006. ArandaSS PolackFP Prevention of pediatric respiratory syncytial virus lower respiratory tract illness: Perspectives for the next decade Front. Immunol 2019 10 1006 Search in Google Scholar

34. The American College of Obstetricians and Gynecologists. Should I get the RSV vaccine during pregnancy?: https://www.acog.org/womens-health/experts-and-stories/ask-acog/should-i-get-the-rsv-vaccine-during-pregnancy. The American College of Obstetricians and Gynecologists Should I get the RSV vaccine during pregnancy? https://www.acog.org/womens-health/experts-and-stories/ask-acog/should-i-get-the-rsv-vaccine-during-pregnancy. Search in Google Scholar

35. American Medical Association. CDC guidelines for maternal RSV vaccine and latest FDA approvals with Sandra Fryhofer, MD: https://www.ama-assn.org/delivering-care/public-health/cdc-guidelines-maternal-rsv-vaccine-and-latest-fda-approvals-sandra. American Medical Association CDC guidelines for maternal RSV vaccine and latest FDA approvals with Sandra Fryhofer, MD https://www.ama-assn.org/delivering-care/public-health/cdc-guidelines-maternal-rsv-vaccine-and-latest-fda-approvals-sandra. Search in Google Scholar

36. Simões EAF, Center KJ, Tita ATN, Swanson, KA, Radley D, Houghton J, et al. Prefusion F protein-based respiratory syncytial virus immunization in pregnancy. N Engl J Med. 2022;386:1615–1626. SimõesEAF CenterKJ TitaATN SwansonKA RadleyD HoughtonJ Prefusion F protein-based respiratory syncytial virus immunization in pregnancy N Engl J Med 2022 386 1615 1626 Search in Google Scholar

37. Palmeira P, Quinello C, Silveira-Lessa AL, Zago CA, Carneiro-Sampaio M. IgG placental transfer in healthy and pathological pregnancies. Clin. Dev. Immunol. 2012;2012:985646. PalmeiraP QuinelloC Silveira-LessaAL ZagoCA Carneiro-SampaioM IgG placental transfer in healthy and pathological pregnancies Clin. Dev. Immunol 2012 2012 985646 Search in Google Scholar

38. Centers for Disease Control and Prevention. RSV vaccine guidance for pregnant people: https://www.cdc.gov/rsv/hcp/vaccine-clinical-guidance/pregnant-people.html. Centers for Disease Control and Prevention RSV vaccine guidance for pregnant people https://www.cdc.gov/rsv/hcp/vaccine-clinical-guidance/pregnant-people.html. Search in Google Scholar

39. Madhi SA, Polack FP, Piedra PA, Munoz FM, Trenholme AA, Simões EAF, et al. Respiratory syncytial virus vaccination during pregnancy and effects in infants. N. Engl. J. Med. 2020;383(5):426–439. MadhiSA PolackFP PiedraPA MunozFM TrenholmeAA SimõesEAF Respiratory syncytial virus vaccination during pregnancy and effects in infants N. Engl. J. Med 2020 383 5 426 439 Search in Google Scholar

40. Bebia Z, Reyes O, Jeanfreau R, Kantele A, Graciela De Leon R, Sánchez MG, et al. Safety and immunogenicity of an investigational respiratory syncytial virus vaccine (RSVPreF3) in mothers and their infants: A phase 2 randomized trial. J. Infect. Dis. 2023;228(3):299–310. BebiaZ ReyesO JeanfreauR KanteleA Graciela De LeonR SánchezMG Safety and immunogenicity of an investigational respiratory syncytial virus vaccine (RSVPreF3) in mothers and their infants: A phase 2 randomized trial J. Infect. Dis 2023 228 3 299 310 Search in Google Scholar

41. Kampmann B, Madhi SA, Munjal I, Simões EAF, Pahud BA, Llapur C, et al. Bivalent prefusion F vaccine in pregnancy to prevent RSV illness in infants. N. Engl. J. Med. 2023;388(16): 1451–1464. KampmannB MadhiSA MunjalI SimõesEAF PahudBA LlapurC Bivalent prefusion F vaccine in pregnancy to prevent RSV illness in infants N. Engl. J. Med 2023 388 16 1451 1464 Search in Google Scholar

42. Centers for Disease Control and Prevention. RSV (Respiratory Syncytial Virus) Immunizations: https://www.cdc.gov/vaccines/vpd/rsv/index.html (2024). Centers for Disease Control and Prevention RSV (Respiratory Syncytial Virus) Immunizations https://www.cdc.gov/vaccines/vpd/rsv/index.html 2024 Search in Google Scholar

43. Centers for Disease Control and Prevention. Vaccines for Children (VFC) Program: https://www.cdc.gov/vitalsigns/vaccines-for-children/index.html. Centers for Disease Control and Prevention Vaccines for Children (VFC) Program https://www.cdc.gov/vitalsigns/vaccines-for-children/index.html. Search in Google Scholar

44. Wodi AP. Advisory committee on immunization practices recommended immunization schedule for children and adolescents aged 18 years or younger — United States, 2024. MMWR Morb. Mortal. Wkly. Rep. 2024;73. WodiAP Advisory committee on immunization practices recommended immunization schedule for children and adolescents aged 18 years or younger — United States, 2024 MMWR Morb. Mortal. Wkly. Rep 2024 73 Search in Google Scholar

45. Centers for Disease Control and Prevention. About the Vaccines for Children (VFC) Program: https://www.cdc.gov/vaccines-for-children/about/index.html. Centers for Disease Control and Prevention About the Vaccines for Children (VFC) Program https://www.cdc.gov/vaccines-for-children/about/index.html. Search in Google Scholar

46. Wilcox CR, Calvert A, Metz J, Kilich E, MacLeod R, Beadon K, et al. Attitudes of pregnant women and healthcare professionals toward clinical trials and routine implementation of antenatal vaccination against respiratory syncytial virus: A multicenter questionnaire study. Pediatr. Infect. Dis. J. 2019;38(9):944–951. WilcoxCR CalvertA MetzJ KilichE MacLeodR BeadonK Attitudes of pregnant women and healthcare professionals toward clinical trials and routine implementation of antenatal vaccination against respiratory syncytial virus: A multicenter questionnaire study Pediatr. Infect. Dis. J 2019 38 9 944 951 Search in Google Scholar

47. Kherfan T, Sallam M. Prospective attitudes towards respiratory syncytial virus (RSV) vaccination: Validation of a survey instrument among young females in Jordan pending vaccine authorization. Vaccines. 2023;11(8):1386. KherfanT SallamM Prospective attitudes towards respiratory syncytial virus (RSV) vaccination: Validation of a survey instrument among young females in Jordan pending vaccine authorization Vaccines 2023 11 8 1386 Search in Google Scholar

48. Limaye RJ, Sauer M, Njogu R, Singh P, Fesshaye B, Karron RA. Characterizing attitudes toward maternal RSV vaccines among pregnant and lactating persons in Kenya: Key considerations for demand generation efforts for vaccine acceptance. J. Pediatr. Infect. Dis. Soc. 2023;12(12):638–641. LimayeRJ SauerM NjoguR SinghP FesshayeB KarronRA Characterizing attitudes toward maternal RSV vaccines among pregnant and lactating persons in Kenya: Key considerations for demand generation efforts for vaccine acceptance J. Pediatr. Infect. Dis. Soc 2023 12 12 638 641 Search in Google Scholar